Neuro-Hitech (NHPI) Reports Cognitive Improvement From Phase Two Clinical Trial of Huperzine A In Alzheimer's Disease Patients
Tweet Send to a Friend
Neuro-Hitech, Inc. (NASDAQ: NHPI) announced top-line results from the double-blind part of a phase 2 clinical trial of Huperzine A ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
